Healthcare Industry News: Acute Coronary Syndrome
News Release - December 6, 2007
Anthera Pharmaceuticals Names Christopher P. Lowe Chief Financial OfficerSAN MATEO, Calif., Dec. 6 (HSMN NewsFeed) -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs for chronic and acute diseases, announced today the appointment of Christopher P. Lowe to the position of Vice President of Administration and Chief Financial Officer. Mr. Lowe will be reporting directly to Paul F. Truex, Anthera's President and Chief Executive Officer. "We are very pleased to add such a talented and seasoned executive to our team," said Paul F. Truex, President and Chief Executive Officer of Anthera Pharmaceuticals. "His strong operational and financial expertise, and his broad experience with the private and public markets, will provide a valuable foundation for our next phase of rapid growth."
Mr. Lowe comes to Anthera from Asthmatx Inc., where he served as Vice President, Finance and Administration and Chief Financial Officer. Previously, he was Corporate Controller and Chief Accounting Officer for Peninsula Pharmaceuticals, Inc. Mr. Lowe also serves on the board of Hansen Medical. Mr. Lowe holds a B.S. in business administration from California Polytechnic State University, San Luis Obispo, and an MBA from Saint Mary's University in Texas.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a privately-held pharmaceutical development company committed to world-class development and commercialization of promising clinical products to address the unmet medical needs of patients with life-threatening chronic and acute inflammatory diseases. In 2006‚ Anthera acquired worldwide rights (except Japan) to a series of clinical and pre-clinical compounds that inhibit the enzymatic activity of members of the phospholipase (PLA2) family -- a group of enzymes responsible for the release of arachidonic acid and subsequent production of leukotrienes‚ prostacyclins and other mediators of inflammation. These highly potent compounds inhibit novel‚ upstream steps in the inflammation cascade and have the potential to address a variety of diseases including: acute chest syndrome‚ acute lung injury‚ acute respiratory distress syndrome‚ atherosclerosis‚ Acute Coronary Syndrome‚ chronic obstructive pulmonary disease and psoriasis. In order to efficiently commercialize this platform‚ Anthera has brought together a proven management team with extensive experience in licensing‚ clinical research‚ development‚ and commercialization of anti-inflammatory products. For more information please visit http://www.anthera.com.
Source: Anthera Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.